Ann: Agreement with MD Anderson for Phase 1B CHM 0201 AML study, page-16

I was impressed by the presentation and good insights form Dr Maiti

interesting they are trying to avoid the need for a transplant as this is the first I’ve heard of this approach

normally aim for mrd - and then transplant

he seemed very enthused by the prospects to improve the standard of care and quickly get this combination treatment as a front line option which sounds a little like a chance of some revenues

I also hadn’t realised that the Chloritoxin and cdh17 nk combos were going to be in the next gen platform chm0301

exciting times in terms of research and this trial goes to show the quality of the team and the assets under development


he said MD Anderson were responsible for the last 9 of 10 treatments approved for AML… best of the best or as Jen says world class

Chimeric has already benefited patients in their early trials and will benefit so many more in the coming years